1 – 10 of 41
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Stakeholder Feedback on the current draft of General Recommendation N° 37 on racial discrimination in the enjoyment of the right to health (GR37) on behalf of The European Association of Health Law (EAHL) Interest Group on Supranational Biolaw
2024)(
- Other contribution › Consultation response
- 2023
-
Mark
Governing, Protecting, and Regulating the Future of Genome Editing : The Significance of ELSPI Perspectives
Slokenberga, Santa ; Minssen, Timo and Nordberg, Ana LU
(2023)
- Book/Report › Anthology (editor)
- 2022
-
Mark
Genome editing in humans : A survey of law, regulation and governance principles
2022)(
- Book/Report › Report
-
Mark
AICARE - AI and Automated systems and the Right to Health : Revisiting law accounting for the exploitation of users’ preferences and values
2022)(
- Contribution to conference › Poster
-
Mark
Syntetisk biologi - en hållbar lösning på klimatkrisen?
2022)(
- Contribution to conference › Poster
-
Mark
Balancing innovation, ‘ordre public’ and morality in human germline editing : A call for more nuanced approaches in patent law
(
- Contribution to journal › Article
- 2021
-
Mark
Biobank and Biomedical Research: Responsibilities of Controllers and Processors under the EU General Data Protection Regulation
2021) p.61-89(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The Role of Patents and Licensing in the Governance of Human Genome Editing: A White Paper
2021)(
- Book/Report › Report
-
Mark
Sweden: Legal Response to Covid-19
2021)(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
General commentary on 'A series of scenarios developed by the World Health Organization (WHO) Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing to both test the utility of, and illustrate how to use, their governance framework'
2021)(
- Other contribution › Consultation response